KR102689774B1 - Composition for improving skin - Google Patents
Composition for improving skin Download PDFInfo
- Publication number
- KR102689774B1 KR102689774B1 KR1020160160307A KR20160160307A KR102689774B1 KR 102689774 B1 KR102689774 B1 KR 102689774B1 KR 1020160160307 A KR1020160160307 A KR 1020160160307A KR 20160160307 A KR20160160307 A KR 20160160307A KR 102689774 B1 KR102689774 B1 KR 102689774B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- extracting
- organic solvents
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 239000000284 extract Substances 0.000 claims abstract description 216
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 50
- 210000003056 antler Anatomy 0.000 claims abstract description 46
- 241000282994 Cervidae Species 0.000 claims abstract description 42
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 39
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 claims abstract description 37
- 230000002087 whitening effect Effects 0.000 claims abstract description 35
- 230000037303 wrinkles Effects 0.000 claims abstract description 34
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 32
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000003960 organic solvent Substances 0.000 claims description 31
- 239000004480 active ingredient Substances 0.000 claims description 28
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000002689 soil Substances 0.000 claims 15
- 150000001298 alcohols Chemical class 0.000 claims 5
- 239000012454 non-polar solvent Substances 0.000 claims 5
- 239000002798 polar solvent Substances 0.000 claims 5
- 230000037394 skin elasticity Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 68
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 28
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 26
- 108010035532 Collagen Proteins 0.000 abstract description 19
- 102000008186 Collagen Human genes 0.000 abstract description 19
- 229920001436 collagen Polymers 0.000 abstract description 19
- 230000015572 biosynthetic process Effects 0.000 abstract description 17
- 238000003786 synthesis reaction Methods 0.000 abstract description 15
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 14
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 14
- 230000036252 glycation Effects 0.000 abstract description 11
- 210000001626 skin fibroblast Anatomy 0.000 abstract description 4
- 230000002000 scavenging effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 57
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 28
- 235000006708 antioxidants Nutrition 0.000 description 26
- 230000006872 improvement Effects 0.000 description 22
- 239000004615 ingredient Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 239000013641 positive control Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 12
- 229930003268 Vitamin C Natural products 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 235000019154 vitamin C Nutrition 0.000 description 12
- 239000011718 vitamin C Substances 0.000 description 12
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- -1 olive oil Chemical compound 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000007760 free radical scavenging Effects 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 229960000271 arbutin Drugs 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 240000002924 Platycladus orientalis Species 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000037319 collagen production Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000003495 polar organic solvent Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283026 Cervus elaphus Species 0.000 description 2
- 241000283007 Cervus nippon Species 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 241000207782 Convolvulaceae Species 0.000 description 2
- 241001609679 Cuscuta japonica Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 241000974009 Cervus canadensis Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000009536 samultang Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
본 발명은 피부 개선용 조성물에 관한 것이다. 본 발명에 따른 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물은 멜라닌 총량을 현저히 감소시켜 미백 효과를 나타내고, 피부의 섬유아세포의 콜라겐 합성을 촉진하며, 엘라스테이즈 활성을 저해하여 주름을 개선하며 탄력을 증진시키고, 산화질소(NO) 생성을 억제하여 항염증 효과를 나타내며, 자유 라디칼을 소거하여 항산화 효과, 당화를 억제하는 항당화 효과를 통해, 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화용 의약, 화장료 또는 식품 제조에 사용할 수 있다.The present invention relates to a composition for improving skin. The mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekjaen extract according to the present invention exhibits a whitening effect by significantly reducing the total amount of melanin, promotes collagen synthesis in skin fibroblasts, and inhibits elastase activity. It improves wrinkles and improves elasticity, suppresses the production of nitric oxide (NO), has an anti-inflammatory effect, has an antioxidant effect by scavenging free radicals, and has an anti-glycation effect that suppresses glycation, thereby whitening skin, improving wrinkles, and improving elasticity. , can be used in the manufacture of medicines, cosmetics or foods for anti-inflammatory, antioxidant and/or anti-glycation purposes.
Description
본 발명은 피부 미백, 탄력 증진, 주름 개선, 항염증, 항산화, 항당화 효과를 나타내는 피부 개선용 조성물에 관한 것이다. The present invention relates to a composition for skin improvement that exhibits skin whitening, elasticity enhancement, wrinkle improvement, anti-inflammatory, antioxidant, and anti-glycation effects.
희고 고운 피부를 갖고자 하는 것은 일반적인 소망이다. 피부의 색깔 또는 밝기는 사람의 피부 내 멜라닌(melanin)의 농도와 분포에 따라 유전적으로 결정되나, 태양 자외선, 피로 또는 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. 멜라닌은 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 촉매로 작용하여 도파(DOPA) 및 도파퀴논(dopaquinone)으로 순차적으로 바뀐 후, 비효소적인 산화반응을 거쳐 만들어진다. 이와 같이 멜라닌이 만들어지는 경로는 알려져 있으나, 멜라닌 합성을 유도하는 메커니즘에서 티로시나제가 촉발되는 원인이 무엇인지에 대해서는 아직도 자세히 밝혀지지 않고 있다. It is a common wish to have white and fair skin. Skin color or brightness is genetically determined by the concentration and distribution of melanin in a person's skin, but is also affected by environmental or physiological conditions such as solar ultraviolet rays, fatigue, or stress. Melanin is made by sequentially converting tyrosine, a type of amino acid, into DOPA and dopaquinone through the enzyme tyrosinase as a catalyst, and then through a non-enzymatic oxidation reaction. Although the path by which melanin is produced is known, the cause of tyrosinase triggering in the mechanism that induces melanin synthesis has not yet been revealed in detail.
한편, 일반적으로 알려진 미백 성분으로서, 코지산(Kojic acid) 또는 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민 C(L-Ascorbic acid) 또는 이들의 유도체와 각종 식물 추출물이 있다. 이들은 멜라닌 색소의 합성을 저해함으로써, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착증의 개선이 가능하다. 그러나 피부 적용 시, 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적인 효과를 기대할 수 없는 문제점이 있다.Meanwhile, commonly known whitening ingredients include substances that inhibit tyrosinase enzyme activity such as kojic acid or arbutin, hydroquinone, vitamin C (L-Ascorbic acid) or their derivatives, and various There are plant extracts. By inhibiting the synthesis of melanin pigment, they can not only brighten skin tone and achieve skin whitening, but also improve skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, or genetics. However, when applied to the skin, there is a limit to the amount of use due to safety issues such as irritation and redness, or the effect is so small that no practical effect can be expected.
또한, 콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로서 세포외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포분할과 분화(유기체의 성장 혹은 상처 치유시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다. 또한, 근래에 들어 피부 노화에 대한 광범위한 연구가 발전되면서 피부에서의 콜라겐의 중요한 기능이 밝혀지고 있다.In addition, collagen is a major matrix protein produced by skin fibroblasts and exists in the extracellular matrix, and its important functions include mechanical rigidity of the skin, connective tissue resistance and tissue adhesion, support for cell adhesion, and cell division and differentiation ( It is known to induce growth of organisms or wound healing. This collagen decreases due to age and photoaging caused by ultraviolet irradiation, and this is known to be closely related to the formation of wrinkles in the skin. In addition, as extensive research on skin aging has developed in recent years, the important functions of collagen in the skin have been revealed.
콜라겐 합성을 촉진하여 주름 개선 효과를 나타내는 유효성분들이 알려져 있다. 예를 들어, 레티노산(retinoic acid), TGF(transforming growth factor)[비특허문헌 1], 동물 태반 유래의 단백질[특허문헌 1], 베튤린산(betulinic acid)[특허문헌 2], 클로렐라 추출물[특허문헌 3, 4] 등이 콜라겐 합성 촉진 물질로서 알려져 있다. 그러나, 상기 유효성분들은 피부 적용 시 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 피부의 콜라겐 합성을 촉진하여 피부 기능을 개선하는 효과를 기대할 수 없는 문제점이 있다.There are known active ingredients that promote collagen synthesis and have a wrinkle-improving effect. For example, retinoic acid, TGF (transforming growth factor) [Non-patent Document 1], protein derived from animal placenta [Patent Document 1], betulinic acid [Patent Document 2], chlorella extract [ Patent Documents 3 and 4] are known as collagen synthesis promoting substances. However, the amount of the active ingredients is limited due to safety issues such as irritation and redness when applied to the skin, or the effect is so minimal that the effect of improving skin function by promoting collagen synthesis in the skin cannot be expected.
또한, 염증은 상처나 질병에 반응하는 인체의 면역 반응으로, 자외선이나 활성산소, 자유라디칼 등의 산화적 스트레스 등이 염증성 인자를 활성화시켜 각종 질병 및 피부의 노화를 일으킨다. 혈관 활성 폴리펩타이드인 키닌(kinin), 플라스민(plasmin) 또는 보체 (complement) 등이 혈관 확장과 수축 및 주화성(chemotaxis) 작용을 하고, 그 외에 인터루킨-6(IL-6) 등과 같은 림포카인과 아라키돈산(arachidonic acid) 등이 염증 반응을 담당한다. 아라키돈산은 싸이클로옥시게나아제(cyclooxygenase) 혹은 리포옥시게나아제(lipooxygenase)의 2가지 경로를 거쳐 염증 매개체인 프로스타글란딘(prostaglandin) 또는 류코트리엔(lukotriene)들로 대사되어 다양한 염증 반응을 매개한다. In addition, inflammation is the body's immune response to wounds or diseases, and oxidative stress such as ultraviolet rays, active oxygen, and free radicals activate inflammatory factors, causing various diseases and skin aging. Vasoactive polypeptides such as kinin, plasmin, or complement have vasodilation and constriction and chemotaxis effects, and lymphocytes such as interleukin-6 (IL-6) Phosphorus and arachidonic acid are responsible for the inflammatory response. Arachidonic acid is metabolized through two pathways, cyclooxygenase or lipooxygenase, into prostaglandins or leukotrienes, which are inflammatory mediators, and mediates various inflammatory reactions.
염증을 소실시키기 위해 염증원의 제거, 생체 반응 및 증상을 감소시키는 작용을 하는 것을 항염제라 한다. 현재까지 항염의 목적으로 이용되고 있는 물질로는 비스테로이드계로 플루폐나믹산(flufenamic acid), 이부프로펜(ibuprofen), 벤지다민(benzydamine) 또는 인도메타신(indomethacin) 등이 있고 스테로이드계통으로 프레드니솔론(prednisolone) 또는 덱사메타손(dexamethasone) 등이 있다. 또한, 알란토인, 아즈엔 또는 하이드로코티손 등이 항염증에 효과가 있는 것으로 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 염증 완화 효과를 기대할 수 없는 문제점이 있다.Anti-inflammatory drugs are called anti-inflammatory drugs that remove inflammation and reduce biological reactions and symptoms. Substances currently used for anti-inflammatory purposes include non-steroids such as flufenamic acid, ibuprofen, benzydamine, or indomethacin, and steroids such as prednisolone. or dexamethasone. In addition, allantoin, Azn or hydrocortisone are known to be effective in anti-inflammatory, but the amount of use of these substances is limited due to safety issues on the skin, or the effect is so minimal that a practical inflammation-relieving effect cannot be expected. There is.
한편, 생체 외부로부터 유입되거나, 생체 내에서 발생하는 활성 산소는 생체의 노화를 촉진시키거나, 암을 발생시키는 등 많은 문제의 원인이 된다. 따라서 활성 산소에 의한 산화를 억제하는 항산화 물질에 대한 개발 및 연구가 많이 이루어 지고 있다. 항산화 물질은 동, 식물계에 널리 분포되어 있으며 과일과 채소에 많은 페놀성 화합물, 플라보노이드, 토코페롤, 비타민 C, 셀레늄 등이 알려져 있다. 다만, 천연에 존재하는 항산화 물질은 피부 적용 시 실질적으로 충분한 효과를 기대할 수 없는 실정이다. 따라서, 항산화력이 뛰어나고 가격이 저렴한 합성 항산화제가 많이 사용되고 있으나, 인체 부작용 등 안전성에 대한 우려로 그 사용이 제한된다. Meanwhile, active oxygen flowing in from outside the body or generated within the body causes many problems, such as accelerating aging of the body or causing cancer. Therefore, much development and research is being conducted on antioxidant substances that inhibit oxidation by active oxygen. Antioxidants are widely distributed in the animal and plant kingdoms, and many phenolic compounds, flavonoids, tocopherols, vitamin C, and selenium are known to be present in fruits and vegetables. However, antioxidant substances that exist in nature cannot be expected to have a substantially sufficient effect when applied to the skin. Therefore, synthetic antioxidants that have excellent antioxidant power and are inexpensive are widely used, but their use is limited due to safety concerns such as side effects on the human body.
당화(Glycation)는 일반적으로 효소의 관여 없이 일어나는 단백질 또는 지방에 포도당 또는 과당과 같은 단순당이 공유결합을 형성하는 반응을 의미한다. 최종당화산물의 축적은 단백질을 단단하고 더욱 부서지기 쉬운 상태로 변화시키며, 당화된 콜라겐은 진피층의 세포 외 기질에서 콜라겐이 적절한 구조를 형성하지 못하도록 함으로써 피부의 탄력을 잃게 하고 주름 생성을 촉진한다[비특허문헌 2]. 또한 당화로 인해 생성된 최종당화산물은 갈색 빛을 띠는 물질로써, 피부 노화가 진행되면서 점차 얼굴빛이 노랗게 변하는 원인 물질로 생각되고 있으며, 특정 최종당화산물이 쌓일수록 피부에서 반사되는 반사 빛이 줄어든다고 알려져 있다[비특허문헌 3]. 당화를 억제하는 물질로 아미노구아니딘(Aminoguanidine), 피리독사민(Pyridoxamine), 아스피린(Aspirin) 등이 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 효과를 기대할 수 없는 문제점이 있다.Glycation generally refers to a reaction in which a simple sugar such as glucose or fructose forms a covalent bond with a protein or fat without the involvement of enzymes. Accumulation of advanced glycation end products changes proteins into a hard and more brittle state, and glycated collagen prevents collagen from forming an appropriate structure in the extracellular matrix of the dermal layer, causing skin to lose elasticity and promoting wrinkles [ Non-patent Document 2]. In addition, the advanced glycation end products produced by glycation are brown-colored substances and are thought to be the cause of the complexion gradually turning yellow as skin aging progresses. As certain advanced glycation end products accumulate, the reflected light reflected from the skin decreases. It is known that [Non-patent Document 3]. Aminoguanidine, Pyridoxamine, and Aspirin are known as substances that inhibit glycation, but these substances have limits on the amount of use due to safety issues on the skin, or their effects are so minimal that they are practically effective. There is a problem that cannot be expected.
또한, 생체에 안전하고, 유효성분이 안정하며, 무엇보다도 기존의 피부 미백, 주름 개선, 탄력 증진, 항염증 및/또는 항산화 효과가 있는 물질보다 효과가 우수한 피부 미백, 주름 개선, 탄력 증진, 항염증 및/또는 항산화 활성을 지닌 성분의 개발이 절실히 요망되고 있다.In addition, it is safe for the body, the active ingredients are stable, and above all, it has better skin whitening, wrinkle improvement, elasticity promotion, and anti-inflammatory effects than existing substances that have skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, and/or antioxidant effects. There is an urgent need for the development of ingredients with and/or antioxidant activity.
한편, 녹각(Cervi Cornu)은 매화록(梅花鹿) Cervus nippon Temminck, 마록(馬鹿) Cervus elaphus Linne 또는 대록(大鹿) Cervus canadensis Erxleben (사슴과 Cervidae)의 골질화된 뿔이다. 혈액순환을 촉진시키고 어혈(瘀血)을 없애주며 신장기능과 간 기능을 도와준다. 또 칼슘을 다량 함유하고 있어 뼈를 튼튼하게 해준다. Meanwhile, Cervi Cornu is the ossified horn of Cervus nippon Temminck, Cervus elaphus Linne, or Cervus canadensis Erxleben (Deer family Cervidae). It promotes blood circulation, eliminates stagnant blood, and helps kidney and liver functions. It also contains a lot of calcium, which helps strengthen bones.
또한, 토사자(Cuscuta japonica Chois)는 메꽃과에 속하는 한해살이 덩굴성 식물인 새삼의 씨앗으로, 새삼씨라고도 한다. 주로 간과 신장을 보호하며 눈을 밝게 해주고, 양기(陽氣)를 도우며 신장 기능을 튼튼하게 해주는 약재로 알려져 있다. 신장이 허약하여 생긴 남성의 성교불능증, 저절로 정액이 흐르는 경우, 몽정(夢精) 등에 효과가 있다. 뼈를 튼튼하게 해주고 허리 힘을 세게 해주며, 신장 기능이 허약하여 허리와 무릎이 시리고 아픈 것을 치료한다. 또한, 오줌소태와 소변을 잘 보지 못하는 질병과 설사를 낫게 하며 당뇨병 치료에도 효과가 있는 것으로도 알려져 있다.In addition, Cuscuta japonica Chois is the seed of Saesam, an annual vine belonging to the Convolvulaceae family, and is also called Saesam seed. It is mainly known as a medicinal herb that protects the liver and kidneys, brightens the eyes, helps positive energy, and strengthens kidney function. It is effective for impotence in men caused by weak kidneys, spontaneous semen flow, and wet dreams. It strengthens the bones, strengthens the back, and treats pain in the back and knees due to weak kidney function. It is also known to cure urinary incontinence, difficulty urinating, and diarrhea, and is also effective in treating diabetes.
또한, 숙지황(REHMANNIAE RADIX PREPARAT)은 지황 Rehmannia glutinosa Liboschitz ex Steudel (현삼과 Scrophulariaceae)의 뿌리를 포제 가공한 것이다. 숙지황은 사물탕(四物湯)의 주요 약재이며 각종 만성병 중 몸이 허약하여 나타나는 내열(內熱), 인후건조(咽喉乾燥), 갈증 등의 증상에 쓰인다In addition, REHMANNIAE RADIX PREPARAT is made by processing the roots of Rehmannia glutinosa Liboschitz ex Steudel (Scrophulariaceae). Rehmannia glutinosa is the main medicinal ingredient in Samultang and is used to treat symptoms such as internal heat, dry throat, and thirst that appear due to weakness in the body among various chronic diseases.
또한, 백자인은 백과 식물 Platycladus orientalis, Thuja orientalis(=Biota orientalis)의 종인(種仁)으로, 정신을 안정되게 하고 대소변을 잘 나오게 하는 약재이다.In addition, Baekjain is a species of the encyclopedia plant Platycladus orientalis, Thuja orientalis (=Biota orientalis), and is a medicinal herb that stabilizes the mind and promotes bowel movement.
이에, 본 발명자들은 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물이 멜라닌 총량을 현저히 감소시켜 미백 효과를 나타내고, 피부의 섬유아세포의 콜라겐 합성을 촉진하며, 엘라스테이즈 활성을 저해하여 주름을 개선하며 탄력을 증진시키고, 산화질소(NO) 생성을 억제하여 항염증 효과를 나타내며, 자유 라디칼을 소거하는 항산화 효과 및 당화를 억제하는 항당화 효과를 확인함으로써 본 발명을 완성하게 되었다.Accordingly, the present inventors found that a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract showed a whitening effect by significantly reducing the total amount of melanin, promoted collagen synthesis in skin fibroblasts, and inhibited elastase activity. The present invention was completed by confirming that it improves wrinkles, improves elasticity, exhibits an anti-inflammatory effect by suppressing nitric oxide (NO) production, and has an antioxidant effect that scavenges free radicals and an anti-glycation effect that inhibits glycation.
따라서, 본 발명의 목적은 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 유효성분으로 포함하는 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화용 조성물을 제공하는데 있다.Therefore, the object of the present invention is to provide a composition for skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation, which contains as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract and Baekjain extract. It is provided.
상기 과제를 해결하기 위한 수단으로서, 본 발명은 의약, 화장료 또는 식품 제조를 위한, 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 유효성분으로 포함하는 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화용 조성물을 제공한다.As a means to solve the above problems, the present invention provides a skin whitening, wrinkle improvement, and elasticity product containing as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract for manufacturing medicine, cosmetics, or food. Provided are compositions for enhancing, anti-inflammatory, antioxidant and/or anti-glycation properties.
본 발명에 따른 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물은 멜라닌 총량을 현저히 감소시켜 미백 효과를 나타내고, 피부의 섬유아세포의 콜라겐 합성을 촉진하며, 엘라스테이즈 활성을 저해하여 주름을 개선하며 탄력을 증진시키고, 산화질소(NO) 생성을 억제하여 항염증 효과를 나타내며, 자유 라디칼을 소거하여 항산화 효과 및 당화를 억제하는 항당화 효과를 나타냄으로써, 의약, 화장료 또는 식품 제조에 사용할 수 있다. The mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekjaen extract according to the present invention exhibits a whitening effect by significantly reducing the total amount of melanin, promotes collagen synthesis in skin fibroblasts, and inhibits elastase activity. It improves wrinkles, improves elasticity, inhibits the production of nitric oxide (NO), has an anti-inflammatory effect, and has an antioxidant effect by scavenging free radicals and an anti-glycation effect by suppressing glycation, making it suitable for manufacturing medicine, cosmetics or food. You can use it.
이하, 본 발명의 구성을 구체적으로 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 성분이 실제 피부에 적용 시 우수한 효과를 발휘하기 위해서는 저농도에서 고활성의 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 활성을 나타내고, 피부를 투과하여 흡수되는 능력이 우수하고, 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 효과를 나타내기에 충분한 시간 동안 머무를 수 있도록 휘발성이 낮고, 조성물이나 피부 상에서 활성 성분이 안정하게 유지되고, 의약, 화장료 또는 식품 등으로의 제조가 용이하며, 또한 피부에 안전한 것이 바람직하다. 그러나, 공지의 성분 중 상기 특성을 모두 만족시키는 성분은 흔치 않다. 예를 들어, 몇몇 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 성분들은 시험관 내 실험 시 저농도에서도 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 활성은 우수하나, 피부를 투과하여 흡수되는 능력이 떨어져 실제 피부에 적용하기엔 어렵다. 또 다른 활성 성분들은 친수성이 낮아 의약이나 화장품, 식품으로 제형화가 어렵다. 또한, 몇몇 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 성분들은 열, 광, 또는 산소에 노출되었을 때 상기 활성 성분이 분해되거나 다른 화합물로 변형되어 피부에 적용하기 전에 이미 효과가 사라지는 경우도 있다. In order for skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation ingredients to have excellent effects when applied to actual skin, they must be highly active at low concentrations for skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation properties. /or exhibit anti-glycation activity, have an excellent ability to penetrate and be absorbed into the skin, and have low volatility so that they remain for a sufficient period of time to exhibit skin whitening, wrinkle improvement, elasticity enhancement, anti-inflammatory, antioxidant and/or anti-glycation effects. , it is desirable that the active ingredient is maintained stably in the composition or on the skin, that it is easy to manufacture into medicine, cosmetics, or food, and that it is safe on the skin. However, among known components, components that satisfy all of the above characteristics are rare. For example, some skin-whitening, wrinkle-improving, elasticity-promoting, anti-inflammatory, antioxidant and/or anti-glycation ingredients have skin-whitening, wrinkle-improving, elasticity-promoting, anti-inflammatory, antioxidant and/or anti-glycation properties even at low concentrations when tested in vitro. It is excellent, but its ability to penetrate and absorb through the skin is low, making it difficult to apply to actual skin. Other active ingredients have low hydrophilicity, making them difficult to formulate into medicines, cosmetics, or foods. In addition, some skin whitening, anti-wrinkle, elasticity-enhancing, anti-inflammatory, antioxidant and/or anti-glycation ingredients may decompose or transform into other compounds when exposed to heat, light, or oxygen, prior to application to the skin. In some cases, the effect disappears.
하기 실시예에서 확인할 수 있는 바와 같이, 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물은 저농도에서 월등히 우수한 멜라닌 총량 감소 효과, 항당화 효과, 콜라겐 합성 촉진 효과, 항염증, 항산화 및/또는 항당화를 위한 의약, 화장료 또는 식품 조성물의 유효성분으로 사용할 수 있다.As can be seen in the examples below, deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekjain extract have a significantly excellent total melanin reduction effect, anti-glycation effect, collagen synthesis promotion effect, anti-inflammatory, antioxidant, and/or anti-glycation effect at low concentrations. It can be used as an active ingredient in pharmaceutical, cosmetic, or food compositions.
따라서, 본 발명은 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 유효성분으로 포함하는 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화용 조성물을 제공한다.Therefore, the present invention provides a composition for skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation, comprising as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract and Baekja extract. .
본 발명에서 녹각은 매화록 Cervus nippon Temminck, 마록 Cervus elaphus Linne 또는 대록 Cervus canadensis Erxleben (사슴과 Cervidae)의 골질화된 뿔로, 학명은 Cervi Cornu이다. 또한, 토사자는 갯실새삼 Cuscuta chinensis Lamark (메꽃과 Convolvulaceae)의 씨로, 학명은 Cuscuta japonica Chois이다. 또한, 숙지황은 지황(地黃)의 뿌리를 쪄서 말린 한약재로서, 학명은 Rehmannia glutinosa (Gaertner) Libosch이다. 백자인은 약은 측백나무 Thuja orientalis Linne (측백나무과 Cupressaceae)의 씨로서 씨껍질을 제거한 것이다.In the present invention, the deer antler is Plum Cervus nippon Temminck, Marok Cervus elaphus Linne or Cervus The ossified horn of canadensis Erxleben (Deer family Cervidae), its scientific name is Cervi Cornu. In addition, Tosaja is a seed of Cuscuta chinensis Lamark (Convolvulaceae), and its scientific name is Cuscuta japonica Chois. In addition, Rehmannia glutinosa is an herbal medicine made by steaming and drying the roots of Rehmannia glutinosa, and its scientific name is Rehmannia glutinosa (Gaertner) Libosch. Baekjain is a medicinal product made from the seeds of Thuja orientalis Linne (Cupressaceae), with the seed coat removed.
상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 또는 백자인 추출물은 당업계에 공지된 방법에 의해 추출될 수 있으며, 그 방법은 특별히 한정되지 않는다. 또는, 시판되고 있는 추출물을 이용할 수 있다.The deer antler extract, Tosa extract, Rehmannia glutinosa extract, or Baekja extract can be extracted by a method known in the art, and the method is not particularly limited. Alternatively, commercially available extracts can be used.
바람직하기로는 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 또는 백자인 추출물은 녹각, 토사자, 숙지황 또는 백자인을 물 및/또는 유기용매로 추출하여 수득한 추출물을 사용할 수 있으며, 상기 유기용매는 극성 유기용매, 비극성 유기용매 또는 이들의 혼합용매일 수 있다. 상기 극성 유기용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트 또는 아세톤일 수 있으며, 비극성 유기용매는 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄일 수 있다. 예를 들어, 상기 탄소수 1 내지 5의 저급 알코올은 메탄올, 에탄올, 프로판올, 부탄올 또는 이소프로판올일 수 있다. Preferably, the deer antler extract, Tosa extract, Rehmannia glutinosa extract, or Baekja extract can be used as an extract obtained by extracting antler, Tosa chinensis, Rehmannia glutinosa, or Baekjae extract with water and/or an organic solvent, and the organic solvent is a polar organic solvent, a non-polar organic solvent, or a non-polar organic solvent. It may be an organic solvent or a mixed solvent thereof. The polar organic solvent may be a lower alcohol having 1 to 5 carbon atoms, ethyl acetate, or acetone, and the nonpolar organic solvent may be ether, chloroform, benzene, hexane, or dichloromethane. For example, the lower alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol, or isopropanol.
일 구체예에서, 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 또는 백자인 추출물은 전술한 추출용매를 이용하여 추출된 1차 추출물을 극성이 다른 추출용매를 이용하여 분획한 분획물을 포함할 수 있다. 예를 들어, 녹각 추출물, 토사자 추출물, 숙지황 추출물 또는 백자인 추출물은 탄소수 1 내지 5의 알코올로 추출한 후, 에테르, 벤젠, 헥산 등의 극성이 다른 용매로 다시 분획한 분획물 일 수 있다. 상기 분획 시 용매는 2종 이상 사용할 수 있으며, 용매의 극성에 따라 순차적으로 사용하거나 혼합하여 사용하여, 각 용매 추출물을 제조할 수 있다. In one embodiment, the deer antler extract, Tosa extract, Rehmannia glutinosa extract, or Baekjain extract may include a fraction obtained by fractionating the primary extract extracted using the above-described extraction solvent using an extraction solvent of different polarity. For example, deer antler extract, Tosa extract, Rehmannia glutinosa extract, or Baekjain extract may be fractions extracted with alcohol having 1 to 5 carbon atoms and then fractionated again with a solvent of different polarity such as ether, benzene, or hexane. Two or more types of solvents can be used during the fractionation, and extracts for each solvent can be prepared by using them sequentially or by mixing them depending on the polarity of the solvents.
본 발명에서, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 상기 여과, 농축 및 건조를 모두 수행할 수 있다. 구체적으로 상기 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있고, 농축은 감압 농축기 등을 이용하여 감압 농축할 수 있으며, 건조는 동결건조법을 수행할 수 있다. In the present invention, the prepared extract or the fraction obtained by performing the fractionation process can be filtered, concentrated, or dried to remove the solvent, and the filtration, concentration, and drying can all be performed. Specifically, the filtration can be performed using filter paper or a vacuum filter, the concentration can be performed under reduced pressure using a vacuum concentrator, etc., and the drying can be performed using a freeze-drying method.
또한, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography) 또는 고성능 액체 크로마토그래피(high performance liquid chromatography) 등의 다양한 크로마토그래피를 이용하여 정제함으로써 추가로 정제된 분획을 얻을 수 있다. In addition, the prepared extract or the fraction obtained by performing the fractionation process may be subjected to silica gel column chromatography, thin layer chromatography, or high performance liquid chromatography. Additional purified fractions can be obtained by purification using various chromatographies.
본 발명의 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물의 혼합 추출물은 녹각 추출물, 토사자 추출물, 숙지황 추출물과 백자인 추출물이 1: 1~5 : 1~5 : 1~5 중량비로 혼합된 것이 바람직하다. 특히, 녹각 추출물, 토사자 추출물, 숙지황 추출물과 백자인 추출물이 1: 1: 1: 1의 중량비로 혼합되는 것이 보다 바람직하다.The mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract of the present invention is preferably a mixture of the antler extract, Tosaja extract, Rehmannia glutinosa extract, and Baekja extract in a weight ratio of 1: 1-5: 1-5: 1-5. . In particular, it is more preferable that the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract are mixed at a weight ratio of 1: 1: 1: 1.
본 발명의 조성물은 의약 제형 제조를 위해 사용할 수 있다.The compositions of the present invention can be used for preparing pharmaceutical formulations.
상기 의약 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액의 형태이거나, 엑스제, 분말제, 과립제, 정제 또는 캅셀제의 형태일 수 있다.The pharmaceutical formulation may be in the form of a solution, suspension or emulsion in oil or aqueous medium, or in the form of extracts, powders, granules, tablets or capsules.
또한, 상기 조성물은 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 성분을 포함할 수 있을 것이다. 추가적인 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 성분을 포함하게 되면 본 발명의 조성물의 피부 재생, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 개선 효과는 더욱 증진될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 본 발명의 한 구체예에서, 상기 조성물은 당업계에 공지된 피부 재생 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베튤린산 및 클로렐라 추출물, 당업계에 공지된 항산화 성분으로서, 토코페롤, 셀레늄, 비타민 C 및 페놀성 화합물, 당업계에 공지된 미백 성분으로서, 코지산(Kojic acid), 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민-C(L-Ascorbic acid) 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가의 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 피부 안전성, 상기 유효성분의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.In addition, the composition may further contain one or more active ingredients that exhibit the same or similar functions. For example, it may include known skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation ingredients. When additional skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation ingredients are included, the skin regeneration, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation improvement effects of the composition of the present invention are reduced. It could be further improved. When adding the above ingredients, skin safety due to combined use, ease of formulation, and stability of the active ingredients can be taken into consideration. In one embodiment of the present invention, the composition includes skin regeneration ingredients known in the art, such as retinoic acid, TGF, protein derived from animal placenta, betulinic acid and chlorella extract, and antioxidant ingredients known in the art, such as tocopherol and selenium. , Vitamin C and phenolic compounds, whitening ingredients known in the art, substances that inhibit tyrosinase enzyme activity such as Kojic acid and Arbutin, Hydroquinone, Vitamin-C (L- Ascorbic acid) and its derivatives and various plant extracts may additionally contain one or two or more ingredients selected from the group consisting of. Additional ingredients may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety and ease of formulation of the active ingredient.
또한, 본 발명의 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다.Additionally, the composition of the present invention may further include a pharmaceutically acceptable carrier.
약학적으로 허용 가능한 담체는 완충액, 주사용 멸균수, 일반 식염수 또는 인산염 완충 식염수, 수크로스, 히스티딘, 염 및 폴리솔베이트 등과 같은 여러 성분을 함유할 수 있다.Pharmaceutically acceptable carriers may contain several ingredients such as buffers, sterile water for injection, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbates.
본 발명의 조성물은 경구 또는 비경구로 투여할 수 있으며, 일반 약학 제제의 형태, 예를 들어, 임상 투여 시 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, various oral and parenteral formulations during clinical administration. When formulated, commonly used fillers and extenders are used. It can be prepared using diluents or excipients such as binders, wetting agents, disintegrants, and surfactants.
경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 의약 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(Calcium carbonate), 수크로스(Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, such as starch, calcium carbonate, and water, in the pharmaceutical composition of the present invention. It can be prepared by mixing sucrose, lactose, gelatin, etc.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogenatin, etc. can be used.
본 발명에 있어서, '미백 효과'라 함은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 말한다.In the present invention, 'whitening effect' refers to not only brightening skin tone by inhibiting the synthesis of melanin pigment, but also improving skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, or genetics.
본 발명에 있어서, '주름 개선 효과'라 함은 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present invention, the 'wrinkle improvement effect' refers to suppressing or inhibiting the formation of wrinkles on the skin or alleviating wrinkles that have already been formed.
본 발명에 있어서, '탄력 증진 효과'라 함은 피부에 대한 탄력성이 증가되는 것으로, 피부 탄력의 손실을 억제 또는 저해하거나, 이미 감소된 탄력을 완화시키는 것을 말한다. In the present invention, the 'elasticity enhancing effect' refers to increasing the elasticity of the skin, suppressing or inhibiting the loss of skin elasticity, or alleviating already reduced elasticity.
본 발명에 있어서, '항염증 효과'라 함은 염증을 억제하는 것을 말한다. 상기 염증은 어떤 자극에 대한 생체조직의 방어반응의 하나로, 조직 변질, 순환 장애와 삼출 및 조직 증식의 세 가지를 병발하는 복잡한 병변을 말한다. 보다 구체적으로 염증은 선천성 면역의 일부이며 다른 동물에서처럼 인간의 선천성 면역은 병원체에 특이적으로 존재하는 세포 표면의 패턴을 인식한다. 식세포는 그런 표면을 가진 세포를 비자기로 인식하고 병원체를 공격한다. 만일 병원균이 신체의 물리적 장벽을 깨고 들어온다면 염증반응이 일어난다. 염증반응은 상처 부위에 침입한 미생물들에 대한 적대 환경을 만드는 비특이적인 방어작용이다. 염증반응에서, 상처가 나거나 외부 감염체가 체내로 들어왔을 때, 초기단계 면역반응을 맡고 있는 백혈구들이 몰려들어 사이토카인을 발현한다. 따라서 세포 내 사이토카인의 발현양이 염증반응 활성화의 지표가 된다. 염증과 관련된 피부질환의 예로는 아토피 피부염, 건선, 방사선, 화학물질 또는 화상 등에 의한 홍반성 질환; 산 화상, 수포성 피부병, 태선 모양 종류 질환 또는 알레르기 등에 의한 가려움증; 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염 또는 원형 탈모증과 같은 염증성 모발 손실; 피부 T-세포 림프종 등이 있으나 이에 제한되는 것은 아니다.In the present invention, 'anti-inflammatory effect' refers to suppressing inflammation. The inflammation is one of the defense responses of biological tissues to certain stimuli, and refers to a complex lesion that occurs together with three factors: tissue degeneration, circulatory failure, exudation, and tissue proliferation. More specifically, inflammation is part of innate immunity, and as in other animals, human innate immunity recognizes patterns on the cell surface that are specific to pathogens. Phagocytes recognize cells with such a surface as non-self and attack the pathogen. If pathogens break through the body's physical barriers, an inflammatory response occurs. The inflammatory response is a non-specific defense function that creates a hostile environment for microorganisms invading the wound area. In an inflammatory response, when a wound occurs or an external infectious agent enters the body, white blood cells responsible for the initial immune response flock in and express cytokines. Therefore, the expression level of intracellular cytokines becomes an indicator of inflammatory response activation. Examples of skin diseases related to inflammation include atopic dermatitis, psoriasis, erythematous diseases caused by radiation, chemicals, or burns; Itching caused by acid burns, blistering skin disease, lichenoid disease, or allergies; Inflammatory hair loss, such as seborrheic eczema, acne rosae, pemphigus vulgaris, erythema multiforme, erythema nodosum, balanitis, vulvovaginitis, or alopecia areata; Cutaneous T-cell lymphoma, etc., but is not limited thereto.
본 발명에 있어서, '항산화 효과'라 함은 세포내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species;ROS)에 의한 세포의 산화를 억제하는 것을 말하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포의 손상이 감소되는 것을 포함한다.In the present invention, 'antioxidant effect' refers to the damage to cells caused by highly reactive free radicals or reactive oxygen species (ROS) due to oxidative stress due to intracellular metabolism or the influence of ultraviolet rays. It refers to inhibiting oxidation and includes removing free radicals or reactive oxygen species to reduce damage to cells.
본 발명에 있어서, '항당화 효과'라 함은 세포에 존재하는 포도당과 단백질이 반응하여 신체 내 단백질 기능이 저하되는 당화(Glycation) 현상을 예방하거나 억제하는 것을 뜻한다.In the present invention, the 'anti-glycation effect' refers to preventing or suppressing the glycation phenomenon in which protein function in the body is reduced by the reaction between glucose and protein present in cells.
본 발명에 있어서, '유효량'이라 함은 손상된 미백 효과를 나타내거나, 주름을 개선하거나, 탄력을 증진시키거나, 염증을 억제하거나, 세포의 산화를 억제 또는 완화하거나, 당화의 생성을 억제할 수 있는 추출물의 양을 의미한다. 본 발명의 조성물이 유효량의 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 포함할 때 바람직한 피부 미백 효과, 주름 개선 효과, 탄력 증진 효과, 항염증 효과, 항산화 효과, 항당화 효과를 제공할 수 있다. 본 발명의 조성물에 포함되는 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 것이다. 예컨대, 상기 조성물이 약학 제형으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 상기 유효성분을 포함할 수 있을 것이다. 따라서, 일일 투여량은 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물의 양을 기준으로 0.1 내지 100 ㎎/㎏이고, 바람직하게는 30 내지 80 ㎎/㎏이고, 더욱 바람직하게는 50 내지 60 mg/kg이며, 하루 1 ∼ 6 회 투여될 수 있다. In the present invention, 'effective amount' refers to the ability to exhibit a damaged whitening effect, improve wrinkles, enhance elasticity, suppress inflammation, inhibit or alleviate cell oxidation, or inhibit the production of glycation. It refers to the amount of extract present. When the composition of the present invention contains an effective amount of a mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract, the desired skin whitening effect, wrinkle improvement effect, elasticity enhancement effect, anti-inflammatory effect, antioxidant effect, and anti-glycation effect are desirable. It can provide an effect. The effective amount of the mixed extract containing the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract included in the composition of the present invention will vary depending on the form in which the composition is commercialized, the method in which the compound is applied to the skin, and the time it remains on the skin. . For example, when the composition is commercialized as a pharmaceutical formulation, it may contain the active ingredient at a higher concentration compared to when it is commercialized as a cosmetic that is routinely applied to the skin. Therefore, the daily dosage is 0.1 to 100 mg/kg, preferably 30 to 80 mg/kg, and more preferably, based on the amount of the mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekjain extract. is 50 to 60 mg/kg and can be administered 1 to 6 times a day.
본 발명의 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention can be used alone or in combination with surgery, radiation therapy, hormone therapy, chemical therapy, and methods using biological response modifiers.
본 발명의 의약 제형은 피부 외용제 제형을 포함할 수 있다. The pharmaceutical formulation of the present invention may include a skin topical formulation.
상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 피부외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. When the mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract is used as an external skin preparation, fatty substances, organic solvents, solubilizers, thickening agents, gelling agents, softeners, antioxidants, suspending agents, and stabilizers are added. topicals, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or it may contain adjuvants commonly used in the field of dermatology, such as lipophilic active agents, lipid vesicles or any other ingredients commonly used in topical preparations for the skin. Additionally, the ingredients may be introduced in amounts commonly used in the field of dermatology.
상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물이 피부 외용제 제형으로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제와 같은 제형을 가질 수 있다.When the mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract is provided in the form of an external skin preparation, it is not limited thereto, but may have a formulation such as an ointment, patch, gel, cream, or spray.
또한, 본 발명의 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화용 조성물은 화장료 제형 제조를 위해 사용될 수 있다.In addition, the composition of the present invention for skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation can be used for manufacturing cosmetic formulations.
상기 화장료 제형은 일반적인 유화 제형 및 가용화 제형의 형태일 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. The cosmetic formulation may be in the form of a general emulsified formulation or solubilized formulation. For example, lotion such as flexible lotion or nourishing lotion, emulsion such as facial lotion, body lotion, etc., cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base, liquid such as nutritional cream, moisture cream, eye cream, etc. It can have formulations such as foundation type, solid type or spray type, powder, makeup remover such as cleansing cream, cleansing lotion, cleansing oil, cleansing foam, soap, body wash, etc.
또한, 상기 화장품은 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetics contain fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, and foaming agents in addition to a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract. (foaming agent), fragrance, surfactant, water, ionic or non-ionic emulsifier, filler, sequestering agent and chelating agent, preservative, vitamin, blocking agent, wetting agent, essential oil, dye, pigment, hydrophilic or lipophilic It may contain auxiliaries commonly used in the field of cosmetology, such as active agents, lipid vesicles or any other ingredients commonly used in cosmetics.
상기 화장료 제형은 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워쉬-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 유효성분을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워쉬-오프 타입의 화장품에 비해 낮은 농도의 상기 유효성분을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 상기 유효성분을 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%(바람직하게는 0.0001 중량% 내지 1 중량%)로 포함할 수 있다. 본 발명의 조성물이 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.The cosmetic formulation may contain a relatively high concentration of the active ingredient in the case of a wash-off type cosmetic such as a makeup remover or detergent in which the active ingredient stays on the skin for a short period of time. On the other hand, in the case of leave-on type cosmetics such as lotions, emulsions, creams, and essences, in which the active ingredients stay on the skin for a long period of time, the active ingredients may be contained at a lower concentration than wash-off type cosmetics. It will be fine. Although not limited thereto, in one embodiment of the present invention, the composition may include the active ingredient in an amount of 0.0001% by weight to 10% by weight (preferably 0.0001% by weight to 1% by weight) based on the total weight of the composition. . When the composition of the present invention contains less than 0.0001% by weight of a mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract, it provides sufficient skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-oxidant properties. The saccharification effect cannot be expected, and if it is included in excess of 10% by weight, unwanted reactions such as allergies may occur or skin safety problems may occur. This is to prevent this.
또한, 본 발명의 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화용 조성물은 식품 제형 제조를 위해 사용될 수 있다.Additionally, the composition for skin whitening, wrinkle improvement, elasticity promotion, anti-inflammatory, antioxidant and/or anti-glycation effect of the present invention can be used to prepare food formulations.
상기 식품 제형은 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품 소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품을 의미한다. The food formulation is made by adding a mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract to food materials such as beverages, teas, spices, gum, and confectionery, or by encapsulating, powdering, or suspending the product. means.
상기 식품 제형은 일상적으로 섭취하는 것이 가능하기 때문에 높은 피부 미백, 주름 개선, 탄력 증진, 항염증, 항산화 및/또는 항당화 효과를 기대할 수 있어 매우 유용하다.Since the above food formulation can be consumed on a daily basis, it is very useful as it can be expected to have high skin whitening, wrinkle improvement, elasticity enhancement, anti-inflammatory, antioxidant and/or anti-glycation effects.
상기 유효성분을 식품첨가물로 사용하는 경우, 상기 녹각 추출물, 토사자 추출물, 숙지황 추출물 및 백자인 추출물을 혼합한 혼합 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When using the active ingredient as a food additive, the mixed extract of the deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract may be added as is or used together with other foods or food ingredients, and may be appropriately prepared according to a conventional method. can be used The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). Generally, when producing a food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw materials. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range. .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There are no special restrictions on the types of foods above. Examples of foods to which the above substances can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, etc. These include alcoholic beverages and vitamin complexes, and include all health foods in the conventional sense.
식품 제형이 음료인 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ∼ 0.04 g, 바람직하게는 약 0.02 ∼ 0.03 g 이다.When the food formulation is a beverage, it may contain various flavoring agents or natural carbohydrates as additional ingredients, like regular beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 mL of the composition of the present invention.
상기 외에 식품 제형은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 식품 제형은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, food formulations include various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonated drinks. It may contain carbonating agents used in. Additionally, the food formulation may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail by examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.
제조예 1: 녹각 추출물의 제조Preparation Example 1: Preparation of deer antler extract
녹각을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 녹각 추출물을 제조하였다.After the deer antler was well dried and cut into pieces, 100 g of the dry weight was placed in a flask and extracted by cold soaking with 1000 g of extraction solvent (distilled water) for 3 days. An antler extract was prepared by filtering the cold-soaked extract through a filter with a pore size of 0.2㎛.
제조예 2: 토사자 추출물의 제조Preparation Example 2: Preparation of Tosaja extract
토사자를 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 토사자 추출물을 제조하였다.After drying well and cutting into small pieces, 100g of the dry weight was placed in a flask and extracted by cold soaking with 1000g of extraction solvent (distilled water) for 3 days. Tosaja extract was prepared by filtering the cold-soaked extract through a filter with a pore size of 0.2㎛.
제조예Manufacturing example 3: 숙지황 추출물의 제조 3: Preparation of Rehmannia glutinosa extract
숙지황(숙건지황)을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 숙지황 추출물을 제조하였다After thoroughly drying and cutting Rehmannia glutinosa, 100 g of dry weight was placed in a flask and extracted by cold immersion with 1000 g of extraction solvent (distilled water) for 3 days. Rehmannia glutinosa extract was prepared by filtering the cold-soaked extract through a filter with a pore size of 0.2㎛.
제조예Manufacturing example 4: 백자인 추출물의 제조 4: Preparation of Baekjain Extract
백자인을 잘 건조하여 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 백자인 추출물을 제조하였다After thoroughly drying and cutting Baekjain, 100 g of the dry weight was placed in a flask and extracted by cold soaking with 1000 g of extraction solvent (distilled water) for 3 days. Baekjain extract was prepared by filtering the cold-soaked extract through a filter with a pore size of 0.2㎛.
제조예Manufacturing example 5: 녹각, 토사자, 숙지황 및 5: Deer antler, Tosaja, Rehmannia glutinosa and 백자인의white person's 혼합 추출물 제조 Mixed extract preparation
제조예 1의 녹각 추출물 10g, 제조예 2의 토사자 추출물 10g, 제조예 3의 숙지황 추출물 10g과 제조예 4의 백자인 추출물 10g을 혼합하여 녹각, 토사자, 숙지황 및 백자인 혼합 추출물을 제조하였다.10 g of the deer antler extract of Preparation Example 1, 10 g of the Tosa extract of Preparation Example 2, 10 g of the Rehmannia glutinosa extract of Preparation Example 3, and 10 g of the Baekja extract of Preparation Example 4 were mixed to prepare a mixed extract of the deer antler, Tosa persimmon, Rehmannia glutinosa, and Baekja extract.
실시예Example 1: 멜라닌 생성 저해 효과 1: Melanin production inhibition effect
멜라닌 생성 저해를 통한 미백 효과를 확인하기 위하여, Lotan R. 외(Cancer Res. 40:3345-3350, 1980)에 기재된 방법에 따라 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에, 추출물을 첨가하여 멜라닌 총량을 측정하였다. 실험 시, 먼저 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도에서 미백 평가를 수행하였다. 음성 대조군으로는 DMSO를, 양성 대조군으로는 알부틴(albutin)을 사용하였다. In order to confirm the whitening effect through inhibition of melanin production, in the culture medium of B-16 mouse melanoma cells according to the method described by Lotan R. et al. (Cancer Res. 40:3345-3350, 1980), The total amount of melanin was measured by adding the extract. During the experiment, toxicity was first evaluated on rat melanoma cells and whitening was evaluated at a non-toxic concentration. DMSO was used as a negative control, and arbutin was used as a positive control.
구체적으로, 시료를 최종 농도가 100 ppm이 되도록 배지에 첨가하고, 알부틴은 100 ppm이 되도록 배지에 첨가한 후 멜라노마 세포를 3일간 배양하였다. 이후, 세포들을 트립신(trypsin) 처리하여 배양용기로부터 떼어내 원심분리한 후, 멜라닌을 추출하였다. 떼어낸 세포는 수산화나트륨 용액(1N 농도) 1 ml를 가하여 10분간 끓여 멜라닌을 녹이고 분광 광도계를 이용하여, 400 nm에서 흡광도를 측정하여 생성된 멜라닌의 양을 측정하였다. Specifically, the sample was added to the medium to a final concentration of 100 ppm, arbutin was added to the medium to a final concentration of 100 ppm, and the melanoma cells were cultured for 3 days. Afterwards, the cells were treated with trypsin, removed from the culture vessel, centrifuged, and melanin was extracted. To the removed cells, 1 ml of sodium hydroxide solution (1N concentration) was added and boiled for 10 minutes to dissolve the melanin. The amount of melanin produced was measured by measuring the absorbance at 400 nm using a spectrophotometer.
상기 멜라닌 양은 단위 세포수당(1×106 cell)의 흡광도로 나타내는 방법으로 측정하였으며, 대조군에 대한 상대적인 멜라닌 총량을 저해율(%)로 계산하고 결과를 하기 표 1에 나타내었으며, 실험은 각각 3회씩 수행하여 평균값으로 나타내었다. The amount of melanin was measured by expressing the absorbance per unit cell ( 1 It was performed and expressed as an average value.
상기 표 1의 결과에서 볼 수 있듯이, 제조예 5의 혼합 추출물은 저농도에서도 뛰어난 멜라닌 총량 감소 효과를 나타내어 미백 용도로 사용할 수 있음을 알 수 있었다. As can be seen from the results in Table 1, the mixed extract of Preparation Example 5 showed an excellent effect of reducing the total amount of melanin even at low concentrations and could be used for whitening purposes.
실시예Example 2: 콜라겐 합성 촉진 효과 2: Effect of promoting collagen synthesis
시료를 인간 유래의 섬유아세포의 배양액에 첨가하여 세포수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit (Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT)를 이용하여 정량하였다.The sample was added to the culture medium of human-derived fibroblasts to confirm the effect of promoting type 1 collagen synthesis at the cellular level. The synthesized collagen was quantified using the PICP EIA kit (Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT).
시료를 최종 농도 10 ppm이 되도록 하여 섬유아세포의 배양배지(DMEM 배지)에 첨가하여 48시간 배양한 후 배양액을 취하여 PICP EIA 키트로 각 농도에서 제1형 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다. The sample was added to the fibroblast culture medium (DMEM medium) at a final concentration of 10 ppm, cultured for 48 hours, the culture medium was taken, and the degree of type 1 collagen synthesis was measured at each concentration using a PICP EIA kit using a spectrophotometer at 450 nm. It was measured in .
효과 비교를 위하여 시료를 처리하지 않은 섬유아세포의 배양 배지(음성대조군)와 비타민 C(양성대조군)를 최종 농도 52.85 ㎍/ml가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. To compare effects, the degree of collagen synthesis was measured in the same manner for samples to which untreated fibroblast culture medium (negative control) and vitamin C (positive control) were added to a final concentration of 52.85 ㎍/ml.
콜라겐 생성 증가율은 음성 대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 2에 나타내었으며, 실험은 4회씩 수행하여 평균값으로 나타내었다.The rate of increase in collagen production was calculated as the ratio of collagen production relative to the negative control group, and the results are shown in Table 2 below. The experiment was performed four times and expressed as the average value.
상기 표 2에 나타난 바와 같이, 제조예 5의 혼합 추출물을 처리한 경우에 콜라겐 합성을 증가시켰고, 일반적으로 콜라겐 합성을 유도하는 것으로 잘 알려진 비타민C를 적용한 경우와 유사한 콜라겐 합성 효과를 나타내었다. As shown in Table 2, treatment with the mixed extract of Preparation Example 5 increased collagen synthesis, and showed a similar effect on collagen synthesis as when applying vitamin C, which is generally known to induce collagen synthesis.
실시예Example 3: 3: 엘라스테이즈Elastase 활성 저해 효과 active inhibitory effect
엘라스틴(Elastin)을 분해하는 효소인 엘라스테이즈(Elastase)의 활성 저해 효과를 다음과 같이 확인하였다.The effect of inhibiting the activity of Elastase, an enzyme that decomposes elastin, was confirmed as follows.
엘라스테이즈(Elastase)는 사람의 백혈구 세포로부터 유래한 엘라스테이즈를 사용하였고, 엘라스테이즈의 기질로 합성 기질인 MeOSuc-Ala-Ala-Pro-Val-pNA를 사용하였다. 완충 용액은 100 mM의 Tris(pH 7.5) 용액을 사용하였다. 엘라스테이즈는 완충용액을 이용하여 최종적으로 0.2 mU을 사용하였다. 또한, 엘라스테이즈의 합성 기질은 DMSO를 이용하여 100 mM 용액을 만든 후 최종 농도가 0.5 mM이 되도록 완충용액을 이용하여 희석하였다. 이때, 양성 대조군은 엘라스테이즈 저해 물질로 알려진 쿼세틴(Quercetin)을 10 ppm 농도로 넣은 것으로 설정하였다. 엘라스테이즈 저해 후보는 최종 농도가 10 ppm이 되도록 첨가하였다. 반응은 96-웰 플레이트에서 진행하였으며, 상온에서 20분간 반응시켰다. 분광 광도계를 이용하여 1분 간격으로 405 nm에서 흡광도를 측정하여, 시간 대비 흡광도의 기울기를 구하여 효소의 활성도로 정하였다. 엘라스테이즈 저해율은 다음 수학식 1과 같이 계산하였다. Elastase derived from human white blood cells was used, and the synthetic substrate MeOSuc-Ala-Ala-Pro-Val-pNA was used as the elastase substrate. A 100 mM Tris (pH 7.5) solution was used as the buffer solution. Elastase was used in a final amount of 0.2 mU using a buffer solution. In addition, the synthetic substrate of elastase was made into a 100mM solution using DMSO and then diluted with a buffer solution to reach a final concentration of 0.5mM. At this time, the positive control was set to include Quercetin, known as an elastase inhibitor, at a concentration of 10 ppm. The elastase inhibition candidate was added to a final concentration of 10 ppm. The reaction was carried out in a 96-well plate and reacted at room temperature for 20 minutes. Absorbance was measured at 405 nm at 1-minute intervals using a spectrophotometer, and the slope of absorbance versus time was determined to determine enzyme activity. The elastase inhibition rate was calculated according to Equation 1 below.
[수학식 1] [Equation 1]
상기 표 3에서 볼 수 있듯이, 제조예 5의 혼합 추출물을 처리한 경우, 양성대조군 보다 효과는 적으나, 엘라스테이즈 활성 저해가 뛰어남을 알 수 있다. 즉, 혼합 추출물은 우수한 엘라스테이즈 활성 저해 효과를 발휘하였다. 따라서, 혼합 추출물은 탄력 증진, 주름 개선을 위한 용도로 사용할 수 있음을 알 수 있었다. As can be seen in Table 3, when the mixed extract of Preparation Example 5 was treated, the effect was less than that of the positive control, but the inhibition of elastase activity was excellent. In other words, the mixed extract showed excellent elastase activity inhibition effect. Therefore, it was found that the mixed extract can be used to improve elasticity and improve wrinkles.
실시예Example 4: 항염 효과 4: Anti-inflammatory effect
항염증 효과 및 피부 트러블 개선 효과를 확인하기 위하여, RAW264.7 세포주 (ATCC number: CRL-2278)를 이용한 GRIESS 법으로 nitric oxide(NO) 생성 억제력 실험을 실시하였다. To confirm the anti-inflammatory effect and skin trouble improvement effect, a nitric oxide (NO) production inhibition test was conducted using the GRIESS method using RAW264.7 cell line (ATCC number: CRL-2278).
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대 배양하고, 웰 하나에 3×105 개씩 들어가도록 24-웰 프레이트에 넣은 후, 24시간 동안 배양하였다. 이어서, 최종 농도 10 ppm의 농도로 시료를 함유한 세포 배지로 교체하였다. 이때, NO-생성 억제 물질인 L-NMMA(L-NG-Monomethylarginine)을 양성 대조군으로 함께 처리하여 30분 동안 배양하였고, 자극원으로 LPS(Lipopolysaccharide)를 1 ㎍씩 처리하여 24시간 동안 배양하였다. 상층액을 100 ㎕씩 취해 96-웰 프레이트에 옮기고, GRIESS 용액을 100 ㎕씩 가해 상온에서 10분간 반응시키고, 540 nm에서의 흡광도를 측정함으로써 NO 억제 효과를 판단하고, NO 생성 저해율(%)은 하기 수학식 2를 이용하여 계산하여 하기 표 4에 나타내었으며, 실험은 각각 3회씩 수행하여 평균값으로 나타내었다. Specifically, RAW264.7 cells, which are mouse macrophages, were subcultured several times, placed in a 24-well plate at 3×10 5 cells per well, and cultured for 24 hours. Then, it was replaced with cell medium containing the sample at a final concentration of 10 ppm. At this time, L-NMMA (L-NG-Monomethylarginine), an NO-production inhibitor, was treated as a positive control and cultured for 30 minutes, and 1 μg of LPS (Lipopolysaccharide) was treated as a stimulant and cultured for 24 hours. Take 100 ㎕ of the supernatant and transfer it to a 96-well plate, add 100 ㎕ of GRIESS solution each and react at room temperature for 10 minutes. The NO inhibition effect is determined by measuring the absorbance at 540 nm, and the NO production inhibition rate (%) is It was calculated using Equation 2 below and shown in Table 4 below, and the experiment was performed three times each and expressed as the average value.
[수학식 2] [Equation 2]
NO 생성 저해율(%)={(음성대조군의 흡광도 - 각 추출물의 흡광도)/음성 대조군의 흡광도} x 100 NO production inhibition rate (%) = {(absorbance of negative control group - absorbance of each extract)/absorbance of negative control group} x 100
상기 표 4에서 볼 수 있듯이, 제조예 5의 혼합 추출물은 대표적인 항염 의약물질인 L-NMMA와 비교하였을 때, 그 활성은 낮으나 천연물질로서 우수한 활성을 나타내어, 피부 트러블 개선에 있어, 항염 효과가 보조적인 역할로 작용하여 상승 효과를 기대할 수 있다.As can be seen in Table 4, the mixed extract of Preparation Example 5 has low activity compared to L-NMMA, a representative anti-inflammatory medicinal substance, but shows excellent activity as a natural substance, and has an anti-inflammatory effect in improving skin troubles. By acting as an antagonist, a synergistic effect can be expected.
실시예Example 5: 항산화 효과- 자유라디칼 소거율 5: Antioxidant effect - free radical scavenging rate
시료의 항산화 작용을 확인하기 위해 자유라디칼 소거 활성을 측정하였다. 자유라디칼 소거 활성은 DPPH를 이용하여 측정하였다 (Blois, Nature 181, 1190, 1958). To confirm the antioxidant activity of the sample, free radical scavenging activity was measured. Free radical scavenging activity was measured using DPPH (Blois, Nature 181, 1190, 1958).
DPPH는 비교적 안정한 자유라디칼로서 라디칼 상태로 존재 시 517㎚에서 최대 흡광을 보이며 라디칼이 소거되면 흡광성을 잃는다. DPPH는 시그마(Sigma)사의 것을 사용하였다.DPPH is a relatively stable free radical. When it exists in a radical state, it shows maximum light absorption at 517 nm and loses light absorption when the radical is eliminated. DPPH was used from Sigma.
먼저, 1.5 mM (0.06 mg/ml)의 표준 DPPH 에탄올 용액을 만들었다. 그리고, 3차 증류수를 이용하여 1000 μg/ml (0.1%) 비타민 C 용액을 만든 다음 1/2씩 연속 희석하여 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98, 0.49 μg/ml 농도의 비타민 C 시료를 만들었다. 또한, 비타민 C와 동일한 농도로 제조예 1~5의 희석액을 준비하였다. 그 다음, 상기 시료와 표준 DPPH 용액을 같은 비율로 첨가하여 잘 교반한 후, 37 ℃에서 30분간 반응시키고 마이크로플레이트 리더(BioTek EL-340)를 이용하여 517㎚에서의 흡광도를 측정하여 IC50을 구하여 하기 표 5에 나타내었다. First, a standard DPPH ethanol solution of 1.5 mM (0.06 mg/ml) was prepared. Then, make a 1000 μg/ml (0.1%) vitamin C solution using tertiary distilled water and then serially dilute it by 1/2 to obtain 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98. , a vitamin C sample with a concentration of 0.49 μg/ml was prepared. In addition, dilutions of Preparation Examples 1 to 5 were prepared at the same concentration as vitamin C. Next, the sample and the standard DPPH solution were added in equal proportions, stirred well, reacted at 37°C for 30 minutes, and the absorbance at 517 nm was measured using a microplate reader (BioTek EL-340) to determine IC 50. The results were obtained and shown in Table 5 below.
IC50(half maximal inhibitory concentration)은 무첨가 대조군(이 경우 DPPH)의 자유라디칼을 50% 제거하는데 필요한 물질의 농도로서, 자유라디칼 소거능을 표현하는 일반적인 방법이다.IC 50 (half maximal inhibitory concentration) is the concentration of the substance required to remove 50% of free radicals in the no-added control group (in this case, DPPH), and is a general way to express free radical scavenging ability.
상기 표 5와 같이, 제조예 5의 혼합 추출물은 제조예 1~4와 비교하였을 때 자유라디칼 소거능이 뛰어났으며, 양성대조군인 비타민 C와 유사한 항산화 효과를 지님을 확인하였다.As shown in Table 5, the mixed extract of Preparation Example 5 had excellent free radical scavenging ability compared to Preparation Examples 1 to 4, and was confirmed to have an antioxidant effect similar to that of vitamin C, a positive control group.
실시예Example 6: 6: 항당화antiglycation 효과 effect
항당화(anti-glycation) 효능을 확인하기 위하여, L-아르기닌(arginine)과 포도당을 이용하여 당화 저해 활성을 측정하였다. To confirm the anti-glycation effect, the glycation inhibition activity was measured using L-arginine and glucose.
먼저, 1M 인산 완충용액(pH 7.4)을 이용하여 1M L-아르기닌, 1M 포도당을 녹여 준비하고 1M 인산 완충용액을 이용하여 시료를 50 ppm이 되도록 희석해서 준비하였다. 1M L-아르기닌과 1M 인산 완충용액을 1 대 4의 비율로 섞은 다음 96-웰 플레이트에 80 μl씩 분주하였다. 여기에 각각 50ppm으로 희석한 시료와 양성대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100 μl씩 첨가하였다. 이 시료들을 잘 섞어준 다음, 마지막으로 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충용액으로 희석한 포도당을 넣은 후, 70 ℃에서 4시간 동안 반응시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420 nm에서 흡광도를 측정하여 당화 정도를 측정하였다. First, 1M L-arginine and 1M glucose were prepared by dissolving them in 1M phosphate buffer solution (pH 7.4), and the sample was diluted to 50 ppm using 1M phosphate buffer solution. 1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1 to 4, and then 80 μl each was dispensed into a 96-well plate. Here, 100 μl each of the sample diluted to 50ppm and 0.01M aminoguanidin to be used as a positive control were added. These samples were mixed well, and finally, glucose diluted with 1M phosphate buffer solution was added so that the final concentration of glucose was 0.1M, and then reacted at 70°C for 4 hours. The degree of glycosylation was measured by measuring the absorbance of the 96-well plate at 420 nm using a spectrophotometer.
하기 수학식 1의 Glycation 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420 nm에서 흡광도를 측정하였다. The Glycation experimental group in Equation 1 below is an experimental group in which 1M L-arginine and 1M glucose were added to induce glycation. To measure the absorbance of the sample itself, only 1M L-arginine and the sample were added without adding glucose and the absorbance was measured at 420 nm. did.
당화 저해 활성은 다음과 같은 수학식 3으로 구할 수 있다. 실험은 각각 3회씩 수행하여 평균값으로 나타내었다. Glycosylation inhibition activity can be obtained using Equation 3 below. Each experiment was performed three times and expressed as the average value.
[수학식 3] [Equation 3]
상기 표 6의 결과에서 볼 수 있듯이, 본 발명에 따른 제조예 5의 혼합 추출물은 항당화 물질로 알려진 Aminoguanidine과 비교할 때, 항당화 효과가 더욱 뛰어남을 알 수 있다. 즉, 혼합추출물은 우수한 항당화 효과를 나타내어 미백 또는 주름 개선에 있어, 항당화 효과가 보조적인 역할로 작용하여 상승 효과를 기대할 수 있다. As can be seen from the results in Table 6, the mixed extract of Preparation Example 5 according to the present invention has a more excellent anti-glycation effect compared to Aminoguanidine, a known anti-glycation substance. In other words, the mixed extract exhibits an excellent anti-glycation effect, so when it comes to whitening or wrinkle improvement, the anti-glycation effect acts as an auxiliary role, so a synergistic effect can be expected.
제제예Example 1: 의약 제제의 제조 1: Preparation of pharmaceutical preparations
1. 정제의 제조1. Preparation of tablets
제조예 5의 혼합 추출물 0.2㎎0.2 mg of mixed extract of Preparation Example 5
옥수수전분 100㎎Corn starch 100mg
유 당 100㎎Lactose 100mg
스테아린산 마그네슘 2㎎ Magnesium stearate 2mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above ingredients, tablets were manufactured by tableting according to a conventional tablet manufacturing method.
제제예Example 2: 화장품의 제조 2: Manufacturing of cosmetics
1. 영양크림의 제조1. Manufacturing of nutritious cream
하기 조성과 같이, 제조예 5의 혼합 추출물을 유효성분으로 포함하는 영양크림을 통상의 방법에 따라 제조하였다.As shown in the following composition, a nutritional cream containing the mixed extract of Preparation Example 5 as an active ingredient was prepared according to a conventional method.
제조예 5의 혼합 추출물 0.2중량%0.2% by weight of mixed extract of Preparation Example 5
베타-1,3-글루칸 5.0 중량%Beta-1,3-glucan 5.0% by weight
밀납 10.0 중량%Beeswax 10.0% by weight
폴리솔베이트60 1.5 중량%Polysorbate 60 1.5% by weight
피이지 60 경화피마자유 2.0 중량%PEG 60 hydrogenated castor oil 2.0% by weight
솔비탄세스퀴올레이트 0.5 중량%Sorbitan sesquioleate 0.5% by weight
유동파라핀 10.0 중량%Liquid paraffin 10.0% by weight
스쿠알란 5.0 중량%Squalane 5.0% by weight
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic/capric triglyceride 5.0% by weight
글리세린 5.0 중량%Glycerin 5.0% by weight
부틸렌글리콜 3.0 중량%Butylene glycol 3.0% by weight
프로필렌글리콜 3.0 중량%Propylene glycol 3.0% by weight
트리에탄올아민 0.2 중량%Triethanolamine 0.2% by weight
방부제 0.05 중량%Preservative 0.05% by weight
색소 0.05 중량%Pigment 0.05% by weight
향료 0.05 중량%Fragrance 0.05% by weight
정제수 to 100 중량%Purified water to 100% by weight
제제예Example 3: 피부 외용제의 제조 3: Preparation of external skin preparations
1. 연고의 제조1. Preparation of ointment
하기 조성과 같이, 제조예 5의 혼합 추출물을 유효성분으로 포함하는 연고를 통상의 방법에 따라 제조하였다.As shown in the composition below, an ointment containing the mixed extract of Preparation Example 5 as an active ingredient was prepared according to a conventional method.
제조예 5의 혼합 추출물 0.5 중량%0.5% by weight of mixed extract of Preparation Example 5
베타-1,3-글루칸 10.0 중량%Beta-1,3-glucan 10.0% by weight
밀납 10.0 중량%Beeswax 10.0% by weight
폴리솔베이트60 5.0 중량%Polysorbate 60 5.0% by weight
피이지 60 경화피마자유 2.0 중량%PEG 60 hydrogenated castor oil 2.0% by weight
솔비탄세스퀴올레이트 0.5 중량%Sorbitan sesquioleate 0.5% by weight
바셀린 5.0 중량%Vaseline 5.0% by weight
유동파라핀 10.0 중량%Liquid paraffin 10.0% by weight
스쿠알란 5.0 중량%Squalane 5.0% by weight
쉐어버터 3.0 중량%Shea butter 3.0% by weight
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic/capric triglyceride 5.0% by weight
글리세린 10.0 중량%Glycerin 10.0% by weight
프로필렌글리콜 10.2 중량%Propylene glycol 10.2% by weight
트리에탄올아민 0.2 중량%Triethanolamine 0.2% by weight
방부제 0.05 중량%Preservative 0.05% by weight
색소 0.05 중량%Pigment 0.05% by weight
향료 0.05 중량%Fragrance 0.05% by weight
정제수 to 100 중량%Purified water to 100% by weight
Claims (20)
A composition for skin whitening containing as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract.
녹각 추출물은 녹각을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
토사자 추출물은 토사자를 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
숙지황 추출물은 숙지황을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
백자인 추출물은 백자인을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물인 피부 미백용 조성물.
According to claim 1,
Antler extract is an extract obtained by extracting deer antler with one or more selected from the group consisting of water and organic solvents,
The soil extract is an extract obtained by extracting the soil soil with one or more selected from the group consisting of water and organic solvents,
Rehmannia glutinosa extract is an extract obtained by extracting Rehmannia glutinosa with one or more selected from the group consisting of water and organic solvents,
Baekjain extract is a composition for skin whitening obtained by extracting Baekjain with one or more selected from the group consisting of water and organic solvents.
유기 용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트, 또는 아세톤을 포함하는 극성용매; 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄을 포함하는 비극성용매; 또는 이들의 혼합용매인 피부 미백용 조성물.
According to claim 2,
The organic solvent may be a polar solvent containing lower alcohols having 1 to 5 carbon atoms, ethyl acetate, or acetone; Non-polar solvents including ether, chloroform, benzene, hexane, or dichloromethane; Or a composition for skin whitening that is a mixed solvent thereof.
조성물은 피부 미백용 의약, 화장료 또는 식품 제조를 위한 것인, 피부 미백용 조성물.
According to claim 1,
The composition is a composition for skin whitening, which is intended for manufacturing medicine, cosmetics or food for skin whitening.
A composition for improving skin elasticity or improving wrinkles, comprising as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract.
녹각 추출물은 녹각을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고
토사자 추출물은 토사자를 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
숙지황 추출물은 숙지황을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
백자인 추출물은 백자인을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물인 피부 탄력 증진 또는 주름 개선용 조성물.
According to claim 5,
Antler extract is an extract obtained by extracting deer antler with one or more selected from the group consisting of water and organic solvents.
The soil extract is an extract obtained by extracting the soil soil with one or more selected from the group consisting of water and organic solvents,
Rehmannia glutinosa extract is an extract obtained by extracting Rehmannia glutinosa with one or more selected from the group consisting of water and organic solvents,
Baekjain extract is a composition for promoting skin elasticity or improving wrinkles, which is an extract obtained by extracting Baekjain with one or more selected from the group consisting of water and organic solvents.
유기 용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트, 또는 아세톤을 포함하는 극성용매; 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄을 포함하는 비극성용매; 또는 이들의 혼합용매인 피부 탄력 증진 또는 주름 개선용 조성물.
According to claim 6,
The organic solvent may be a polar solvent containing lower alcohols having 1 to 5 carbon atoms, ethyl acetate, or acetone; Non-polar solvents including ether, chloroform, benzene, hexane, or dichloromethane; Or a composition for improving skin elasticity or improving wrinkles, which is a mixed solvent thereof.
조성물은 피부 탄력 증진 또는 주름 개선용 의약, 화장료 또는 식품 제조를 위한 것인, 피부 탄력 증진 또는 주름 개선용 조성물.
According to claim 5,
The composition is a composition for improving skin elasticity or improving wrinkles, which is intended for the manufacture of medicines, cosmetics, or foods for improving skin elasticity or improving wrinkles.
An anti-inflammatory composition containing as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract.
녹각 추출물은 녹각을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
토사자 추출물은 토사자를 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
숙지황 추출물은 숙지황을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
백자인 추출물은 백자인을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물인 항염증용 조성물.
According to clause 9,
Antler extract is an extract obtained by extracting deer antler with one or more selected from the group consisting of water and organic solvents,
The soil extract is an extract obtained by extracting the soil soil with one or more selected from the group consisting of water and organic solvents,
Rehmannia glutinosa extract is an extract obtained by extracting Rehmannia glutinosa with one or more selected from the group consisting of water and organic solvents,
Baekjae extract is an anti-inflammatory composition obtained by extracting Baekjae with one or more selected from the group consisting of water and organic solvents.
유기 용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트, 또는 아세톤을 포함하는 극성용매; 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄을 포함하는 비극성용매; 또는 이들의 혼합용매인 항염증용 조성물.
According to claim 10,
Organic solvents include polar solvents including lower alcohols having 1 to 5 carbon atoms, ethyl acetate, or acetone; Non-polar solvents including ether, chloroform, benzene, hexane, or dichloromethane; Or an anti-inflammatory composition that is a mixed solvent thereof.
조성물은 항염용 의약, 화장료 또는 식품 제조를 위한 것인, 항염증용 조성물.
According to clause 9,
The composition is an anti-inflammatory composition for the manufacture of anti-inflammatory medicine, cosmetics or food.
An antioxidant composition containing as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract.
녹각 추출물은 녹각을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
토사자 추출물은 토사자를 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
숙지황 추출물은 숙지황을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
백자인 추출물은 백자인을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물인 항산화용 조성물.
According to claim 13,
Antler extract is an extract obtained by extracting deer antler with one or more selected from the group consisting of water and organic solvents,
The soil extract is an extract obtained by extracting the soil soil with one or more selected from the group consisting of water and organic solvents,
Rehmannia glutinosa extract is an extract obtained by extracting Rehmannia glutinosa with one or more selected from the group consisting of water and organic solvents,
Baekjae extract is an antioxidant composition obtained by extracting Baekjae with one or more selected from the group consisting of water and organic solvents.
유기 용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트, 또는 아세톤을 포함하는 극성용매; 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄을 포함하는 비극성용매; 또는 이들의 혼합용매인 항산화용 조성물.
According to claim 14,
The organic solvent may be a polar solvent containing lower alcohols having 1 to 5 carbon atoms, ethyl acetate, or acetone; Non-polar solvents including ether, chloroform, benzene, hexane, or dichloromethane; Or an antioxidant composition that is a mixed solvent thereof.
조성물은 항산화용 의약, 화장료 또는 식품 제조를 위한 것인, 항산화용 조성물.
According to claim 13,
The composition is an antioxidant composition for the manufacture of antioxidant medicine, cosmetics or food.
An anti-glycation composition containing as an active ingredient a mixed extract of deer antler extract, Tosa extract, Rehmannia glutinosa extract, and Baekja extract.
녹각 추출물은 녹각을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
토사자 추출물은 토사자를 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
숙지황 추출물은 숙지황을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물이고,
백자인 추출물은 백자인을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물인 항당화용 조성물.
According to claim 17,
Antler extract is an extract obtained by extracting deer antler with one or more selected from the group consisting of water and organic solvents,
The soil extract is an extract obtained by extracting the soil soil with one or more selected from the group consisting of water and organic solvents,
Rehmannia glutinosa extract is an extract obtained by extracting Rehmannia glutinosa with one or more selected from the group consisting of water and organic solvents,
Baekjae extract is an anti-glycation composition obtained by extracting Baekjae with one or more selected from the group consisting of water and organic solvents.
유기 용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트, 또는 아세톤을 포함하는 극성용매; 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄을 포함하는 비극성용매; 또는 이들의 혼합용매인 항당화용 조성물.
According to claim 18,
Organic solvents include polar solvents including lower alcohols having 1 to 5 carbon atoms, ethyl acetate, or acetone; Non-polar solvents including ether, chloroform, benzene, hexane, or dichloromethane; Or a composition for anti-glycation that is a mixed solvent thereof.
조성물은 항당화용 의약, 화장료 또는 식품 제조를 위한 것인, 항당화용 조성물.According to claim 17,
The composition is an anti-glycation composition for the manufacture of anti-glycation drugs, cosmetics or foods.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160160307A KR102689774B1 (en) | 2016-11-29 | Composition for improving skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160160307A KR102689774B1 (en) | 2016-11-29 | Composition for improving skin |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180060609A KR20180060609A (en) | 2018-06-07 |
KR102689774B1 true KR102689774B1 (en) | 2024-07-31 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102282748B1 (en) | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening | |
KR101835739B1 (en) | Composition comprising extracts or fractions of Artemisia capillaris as an effective ingredient | |
KR20170025375A (en) | Composition for improving skin | |
JP2011195502A (en) | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent | |
KR102577528B1 (en) | Composition for improving skin | |
KR20180060611A (en) | Composition for improving skin | |
KR102183896B1 (en) | Composition for improving skin | |
KR20210117247A (en) | Composition for improving skin comprising stevioside as active ingredient | |
KR101989479B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR102689774B1 (en) | Composition for improving skin | |
KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
KR20170137560A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170136933A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR20170025355A (en) | Composition for improving skin | |
KR20180060607A (en) | Composition for improving skin | |
KR20180060610A (en) | Composition for improving skin | |
KR101720712B1 (en) | Composition for improving skin comprising levistilide A | |
KR102000516B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR102002544B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20180060609A (en) | Composition for improving skin | |
KR20170045085A (en) | Composition for improving skin and its use | |
KR101978665B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR102090689B1 (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component alpha-fenchone for Skin Benefit Ingredient | |
KR102472093B1 (en) | Composition for improving skin | |
KR102000515B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |